Insmed Analyst Price Targets - Benzinga

Insmed Inc

INSMNASDAQ

Trade with Public

Trade with Public

$126.29

-0.39-0.31%

At close: Sep 4, 5:00 PM EST

$126.29

N/A

After Hours: Sep 4, 5:04 PM EST

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Insmed Analyst Price Targets

Wall Street analyst price targets and consensus rating for Insmed (INSM).

Price Target Range — 7 Quarters

Analyst Consensus — 21 Analysts

21Buy

Consensus RatingBuy# Analysts21Avg. Consensus PT$199Upside to Avg. PT+57.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 10, 2026	JP Morgan	Jessica Fye	PT Cut	Overweight	$179→$175
Aug 10, 2026	Truist Securities	Danielle Brill	PT Raise	Buy	$185→$195
Aug 7, 2026	Guggenheim	Vamil Divan	PT Cut	Buy	$207→$205
Aug 7, 2026	Wells Fargo	Benjamin Burnett	PT Raise	Overweight	$161→$169
Aug 7, 2026	Evercore ISI Group	Josh Schimmer	PT Raise	Outperform	$160→$170
Jul 21, 2026	BMO Capital	Connor Mackay	Initiate	Outperform	$192
Jul 15, 2026	Wells Fargo	Benjamin Burnett	PT Raise	Overweight	$160→$161
Jul 10, 2026	Guggenheim	Vamil Divan	Maintained	Buy	$207
Jun 22, 2026	Evercore ISI Group	Josh Schimmer	PT Cut	Outperform	$162→$160
Jun 8, 2026	JP Morgan	Jessica Fye	PT Cut	Overweight	$180→$179
Jun 5, 2026	RBC Capital	Leonid Timashev	PT Cut	Outperform	$205→$195
May 14, 2026	Truist Securities	Danielle Brill	PT Cut	Buy	$205→$185
May 8, 2026	RBC Capital	Leonid Timashev	PT Cut	Outperform	$220→$205
May 8, 2026	Wells Fargo	Benjamin Burnett	PT Cut	Overweight	$177→$160
May 8, 2026	Guggenheim	Vamil Divan	PT Cut	Buy	$230→$226
Apr 17, 2026	Roth Capital	Adam Walsh	Maintained	Buy	$212
Apr 14, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$212→$216
Apr 1, 2026	Barclays	Eliana Merle	PT Raise	Overweight	$231→$237
Mar 30, 2026	Morgan Stanley	Matthew Harrison	Upgrade	Equal-Weight→Overweight	$166→$212
Mar 26, 2026	HC Wainwright & Co.	Andrew S. Fein	PT Raise	Buy	$230→$245

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on Insmed, Lowers Price Target to $175

JP Morgan analyst Jessica Fye maintains Insmed (NASDAQ:INSM) with a Overweight and lowers the price target from $179 to $175.

Benzinga Newsdesk

PRO
Truist Securities Reiterates Buy on Insmed, Raises Price Target to $195

Truist Securities analyst Danielle Brill reiterates Insmed (NASDAQ:INSM) with a Buy and raises the price target from $185 to $195.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Insmed, Lowers Price Target to $205

Guggenheim analyst Vamil Divan maintains Insmed (NASDAQ:INSM) with a Buy and lowers the price target from $207 to $205.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Insmed, Raises Price Target to $169

Wells Fargo analyst Benjamin Burnett maintains Insmed (NASDAQ:INSM) with a Overweight and raises the price target from $161 to $169.

Benzinga Newsdesk

PRO
Evercore ISI Group Maintains Outperform on Insmed, Raises Price Target to $170

Evercore ISI Group analyst Josh Schimmer maintains Insmed (NASDAQ:INSM) with a Outperform and raises the price target from $160 to $170.

Benzinga Newsdesk

This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Top Wall Street analysts change outlook on top stocks. For analyst rating changes, see https://www.benzinga.com/analyst-stock-ratings. INSM initiated with $192 PT.

Avi Kapoor